Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastoma

On November 16, 2026 Renaissance Pharma Limited (Renaissance Pharma), an Essential Pharma company focused on development stage assets, reported that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for use of daretabart (hu14.18K322A) in combination with induction chemotherapy, for the first-line treatment of paediatric patients with newly diagnosed high-risk neuroblastoma (HRNB).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This designation was supported by Phase II data published in the Journal of Clinical Oncology in December 20211. The study was an open label, single arm Phase II trial at one centre in 64 children with newly diagnosed HRNB. Three-year event-free survival (EFS) was 73.7% (95% CI 60.0 to 83.4) and three-year overall survival (OS) was 86.0% (95% CI 73.8 to 92.8). Grade 3 or 4 toxicities attributed to the antibody infusion during induction included pain (10% of 379 cycles), hypoxia (6%), infusion related reactions (4%), hypotension (3%) and cough (1%).

The FDA’s BTD program is intended to expedite the development and review of investigational medicines with clinical evidence that may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

Simon Ball, President of Renaissance Pharma said, "We look forward to executing our clinical development strategy, including our ongoing SHINE study in relapsed and refractory disease, together with our future planned induction study, to bring this antibody to the neuroblastoma community."

About Daretabart (Hu14.18K322A)

Daretabart (hu14.18K322A) is an anti-GD2 monoclonal antibody in development for the treatment of high-risk neuroblastoma (HRNB), a rare paediatric cancer. Daretabart is being developed by Renaissance Pharma under an exclusive license agreement with St. Jude Children’s Research Hospital, a global leader in paediatric cancer research and treatment. The antibody targets GD2, a cell surface antigen highly expressed on neuroblastoma cells.

About Neuroblastoma

Neuroblastoma is the most common extracranial solid tumour in children and the most common cancer in children under one year of age. Each year, more than 1,500 people are diagnosed in Europe and approximately 800 in the United States. Approximately half of all neuroblastoma patients have high risk (HRNB) disease for which the long-term survival rates from the time of diagnosis are still only around 50%. The current standard of care is intensive and multimodal, including chemotherapy, surgery, radiotherapy, stem cell transplantation and anti-GD2 monoclonal antibody (mAb) treatment. Despite these interventions, a significant unmet medical need persists in HRNB, with survival remaining lower than in other risk group.

(Press release, Renaissance Pharma, NOV 16, 2026, View Source [SID1234674792])

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026

On November 16, 2026 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, reported that two posters featuring GLIX1 were presented at the 31st Society for Neuro-Oncology (SNO) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data presented at this year’s SNO Annual Meeting further strengthen our belief in GLIX1 as a treatment for GBM. In parallel, our Phase 1/2a study is progressing very rapidly with no identified safety concerns, and we continue to look forward to results from the study in the first half of next year," said Philip Serlin, Chief Executive Officer of BioLineRx. "We are particularly excited about the new window of opportunity cohorts being introduced into the study. Together with our new PK/PD data from the pre-clinical model, the data from these patients are expected to provide valuable information regarding exposure and activity in brain tumors."

"The consistency and magnitude of GLIX1’s antitumor activity across multiple GBM models are highly encouraging and further support the therapeutic rationale for its novel TET2-activating mechanism," said Adam Robertson, Ph.D., Chief Scientific Officer of Hemispherian AS. "Particularly notable is the activity observed in the TMZ-resistant patient-derived model, as well as evidence of brain penetration and dose-dependent increases in tumor 5hmC, a marker of TET2 activity, in the orthotopic model, which strengthen the scientific rationale for advancing GLIX1 in glioblastoma."

Presentation Summaries:

Title: Phase 1/2a study of GLIX1, a novel first-in-class oral TET2 activator, for the treatment of recurrent or progressive high-grade glioma (CTNI-25)

Summary: This poster describes the design of the ongoing Phase 1/2a clinical study (NCT07464925) and highlights the mechanistic and pre-clinical data supporting the rationale for GLIX1 in GBM.

GLIX1-C101 is an open-label, multicenter, first-in-human study consisting of a dose-escalation phase followed by a dose-expansion phase. The study is designed to determine the recommended dose of GLIX1 as monotherapy based on assessments of safety, tolerability, disease characteristics, pharmacokinetics, pharmacodynamics and preliminary clinical activity in patients with high-grade diffuse glioma whose disease has progressed during or recurred following prior standard-of-care or investigational therapies.

The dose escalation part of the study will be followed by a dose expansion part, with doses and populations to be determined based on the first part of the study. Long-term survival follow-up is also included in the study.

The study is ongoing, with dosing initiated in the fourth cohort. No significant treatment-emergent adverse events have been observed.

Notably, remaining cohorts will include patients in a window-of-opportunity setting, providing an opportunity to directly assess GLIX1 brain penetration and biological activity in human tumor tissue, helping inform further clinical development.

Title: GLIX1, a TET2 activator targeting DNA damage response: potent anti-tumor activity across multiple glioblastoma models; orthotopic CDX models and a subcutaneous TMZ-resistant PDX model (EXTH-31)

Summary: This poster highlights the antitumor activity of GLIX1, a first-in-class, oral, brain-penetrant TET2 activator, across three orthotopic glioblastoma cell-derived xenograft (CDX) studies and a subcutaneous, temozolomide (TMZ)-resistant patient-derived xenograft (PDX) model.

In the SNB19 CDX model, GLIX1 demonstrated tumor eradication and prolonged survival. In the U87MG CDX model, GLIX1 produced dose-dependent tumor growth inhibition. In the TMZ-resistant BN2276 PDX model, GLIX1 also demonstrated tumor growth inhibition, compared to control, while TMZ was not effective.

Supporting these efficacy findings, additional pharmacokinetic and pharmacodynamic analyses in the orthotopic U87MG model demonstrated that GLIX1 was detected in the brain at all tested dose levels following oral administration, with total exposure increasing at higher doses. GLIX1 also produced dose-dependent increases in tumor genomic 5-hydroxymethylcytosine (5hmC), a marker of TET2 activity, which correlated with tumor growth inhibition.

Collectively, these preclinical findings demonstrate potent antitumor activity across multiple GBM models, including TMZ-resistant disease, supported by evidence of brain penetration and pharmacodynamic activity consistent with TET2 activation.

(Press release, BioLineRx, NOV 16, 2026, View Source [SID1234674817])

Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly

On November 16, 2026 Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, reported that it has entered into a multi-target multi-modality strategic research collaboration and license agreement with Eli Lilly and Company ("Lilly"). Stipple Bio will leverage its innovative Pointillist Platform and extensive research experience to discover novel tumor-specific cell surface epitope binders, which Lilly will combine with its proprietary oncology technologies to advance high therapeutic index compounds across multiple modalities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Stipple Bio’s Pointillist Platform identifies novel tumor-specific cell surface epitope binders to enable the development of high therapeutic index oncology therapies that selectively target tumor cells, with the potential to increase efficacy and reduce on-target, off-tumor toxicity.

"Stipple Bio was founded with the belief that epitope-level precision could distinguish tumor cells from healthy tissue, unlocking a new generation of effective and safer cancer therapies directed at targets whose expression on healthy cells has historically limited their clinical utility," said Jeff Landau, Chief Executive Officer of Stipple Bio. "Lilly brings tremendous expertise in oncology drug discovery and development. We look forward to working with Lilly’s exceptional oncology team and technologies to bring a new generation of precision cancer therapies to patients."

​​​Landau added, "​This collaboration represents an important step in realizing the broad therapeutic opportunities enabled by our platform, while allowing us to continue advancing our pipeline."​​​

Terms of the Agreement

Under the terms of the agreement, Stipple Bio will receive an upfront payment and an equity investment in Stipple Bio. Lilly receives exclusive worldwide rights to develop and commercialize products arising from the collaboration. Stipple Bio will be eligible to ​receive aggregate payments of up to $5.9 billion dollars upon achievement of research, product development and commercialization milestones, as well as tiered royalties on product sales should Lilly successfully commercialize therapies from the collaboration.

(Press release, Stipple Bio, NOV 16, 2026, View Source [SID1234674850])

HCW Biologics Reports Third Quarter 2026
Business and Clinical Development Highlights and Financial Results

On November 16, 2026 HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, reported financial results and recent business highlights for the three and nine months ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company featured two of its preclinical, non-Fc TRBC molecules at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) ("SITC2026") which took place from November 4 – 8, 2026 in Phoenix, Arizona. In addition, the Company showcased the uniqueness of its TRBC platform to create novel multivalent non-Fc fusion molecules for solid tumor and senescence-associated diseases therapies.

The submission for the Company’s second-generation, tetravalent immune checkpoint inhibitor, HCW11-040, was recognized by SITC (Free SITC Whitepaper)2026 as one of the top 150 abstracts out of over 1,200 abstracts submitted for its scientific rigor, novelty, clarity and potential impact on cancer immunotherapy. In the Poster presentation of its T Cell Engager Program, the Company shared the newly discovered, distinctive features of its lead product candidate in this program, HCW11-018b, including capabilities to induce/promote tertiary lymphoid structure formation inside tumors, convert immunological "cold" tumors into "hot" tumors, and enhance T-cell activation and tumor infiltration while mitigating immunosuppression, using subcutaneous ("s.c.") administration.

In the three months ended September 30, 2026, the Company activated an additional clinical site to participate in the HCW9302 Phase 1 clinical study in alopecia areata and continued patient enrollment and treatment in the third dose cohort (i.e., eight (8) micrograms/kg body weight). In patients treated to date, the s.c. administration of HCW9302 has been well-tolerated and has had no dose-limiting toxicities. With continued patient enrollment, the Phase 1 readout and determination of the Recommended Phase 2 Dose are expected in the first quarter of 2027. The Company intends to present the full results of the Phase 1 clinical trial in an invited oral presentation at the 9th Treg-Directed Therapies Summit in March 2027 in Boston, Massachusetts.

Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, "Progress continues steadily for our clinical study evaluating HCW9302 in alopecia areata, and we are encouraged by results in humans that are consistent with our preclinical studies. We have the support of strong clinical sites who share our passion for developing breakthrough immunotherapeutics. With the addition of a third clinical site, we are hopeful that patient enrollment will maintain a good momentum as we come to the end of the Phase 1 clinical study. We are also excited about the great progress we have made with the molecules we have constructed using our TRBC platform, especially our lead T-cell engager, HCW11-018b, and our lead second-generation immune-checkpoint inhibitor, HCW11-040, which have the potential of revolutionizing treatment for solid tumors and senescence-associated diseases."

Business and Clinical Development Highlights

In the nine months ended September 30, 2026, the Company raised $8.6 million of equity financing, which allowed it to continue to support a Phase 1 clinical study to evaluate HCW9302 in an autoimmune disease and advance preclinical programs, especially the Company’s T-Cell Engager Program. On November 4, 2026, the Company secured up to $10.0 million in cash through debt financing, and received $3.0 million, less transaction costs, at closing and access to an additional $7.0 million, subject to certain conditions. With this financing, the Company believes it has funding in place to reach the milestone of completion of the Phase 1 clinical trial for HCW9302 and determining the Recommended Phase 2 Dose level, which are expected in the first quarter of 2027

As a result of discussions at a recent Type B meeting with the U.S. Food and Drug Administration ("FDA"), the FDA provided the Company with clear guidance for the next steps to prepare its IND application to support a first-in-human clinical study to evaluate HCW11-018b in solid tumors, which the Company intends to file in the first half of 2027. In support of potential upcoming clinical trials, the Company has initiated cGMP manufacturing of HCW11-018b. HCW Biologics has created a high-expression production cell line and a streamlined GMP manufacturing process, utilizing a relatively simple manufacturing process that is similar to the process used to make therapeutic monoclonal antibodies.

Third Quarter 2026 Financial Results

Revenues: Revenues for the three months ended September 30, 2025 and 2026 were $15,606 and $55,463, respectively. Revenues in the nine months ended September 30, 2025 and 2026 were $27,222 and $6.7 million, respectively. In the three and nine months ended September 30, 2025, at the request of the licensee, the Company agreed to suspend the license with AlloTera Therapeutics, Inc. ("AlloTera Therapeutics"), thus the Company recognized revenues related only to minor ancillary services such as storage. In the nine months ended September 30, 2026, the Company elected to terminate the license with AlloTera Therapeutics and recaptured the exclusive rights to the licensed molecules. In the nine months ended September 30, 2026, the Company completed the closing of the exclusive, worldwide licensing agreement with Beijing Trimmune Biotech Co., Ltd. ("Trimmune") for the in vivo rights for HCW11-006 ("Trimmune License") and performed additional post-transfer services under the agreement.

Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2025 and 2026 were $1.4 million and $1.2 million, respectively, a decrease of $161,670, or 12%. The decrease was primarily due to decreases in salaries, benefits and related taxes and preclinical expenses. R&D expenses for the nine months ended September 30, 2025 and 2026 were $4.1 million and $3.7 million, respectively, a decrease of $405,905, or 10%. The decrease was primarily due to a decline in manufacturing and materials expenses, partially offset by increases in taxes and salaries, benefits and related expenses.

General and administrative (G&A) expenses: G&A expenses for the three months ended September 30, 2025 and 2026 were $1.8 million and $1.4 million, respectively, a decrease of $518,608, or 28%. The decrease was primarily attributable to decreases in stock-based compensation expense and a decline in fees paid for professional services, such as corporate legal advice, legal advice for prosecution of patents, auditing and tax services, and other professional services. G&A expenses for the nine months ended September 30, 2025 and 2026, were $6.2 million and $5.1 million, respectively, a decrease of $1.1 million, or 18%. The decrease was primarily attributable to decreases in stock-based compensation expense, professional services and insurance premiums.

Legal expenses (recoveries), net: Legal expenses and recoveries, net represent the legal fees that the Company incurred for an Arbitration, net of insurance recoveries. In the nine months ended September 30, 2025, the Company received a $2.0 million insurance recovery, partially offset by $409,055 of legal expenses. In the nine months ended September 30, 2026, there were expenses of $14,483. The Company anticipates it will continue to incur some expenses for the costs of remaining in compliance with the terms of the Settlement and Release Agreement from the Arbitration, primarily due to requirements for patents which are necessary to protect the Company’s exclusive, worldwide intellectual property rights held in perpetuity.

Nonoperating changes impacting net income (loss): In the three months ended September 30, 2025, the was a decrease in fair value of $966,284 related to the change in the fair value of the Company’s shares in AlloTera Therapeutics and the related contingent liability, and a loss of $182,146 on the sale of put shares through the Company’s Standby Equity Purchase Agreement. In the three months ended September 30, 2026, there was a $494,683 loss on the return of equipment

In the nine months ended September 30, 2025, there was an increase in fair value of $782,404 related to the change in fair value of the Company’s shares in AlloTera Therapeutics and the related contingent liability, a loss of $182,146 on the sale of put shares through the Company’s Standby Equity Purchase Agreement. In the nine months ended September 30, 2026, there was a $1.8 million nonoperating loss, primarily consisting of a $1.8 million decrease in the fair value of a warrant liability, which was reclassified to equity in this period.

Net loss: Net loss for the three months ended September 30, 2025 and 2026 was $4.6 million and $3.2 million, respectively. Net loss for the nine months ended September 30, 2025 and 2026, was $8.7 million and $5.0 million, respectively.

Financial Guidance

As of September 30, 2026, the Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support. We considered future elements of our financing plan, but we cannot be assured that we will continue to have success with remaining elements of our plan.

On June 26, 2025, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company was in compliance with Listing Rule 5550(b)(1) (the "Equity Rule"). On October 2, 2026, the Company received formal notice from Nasdaq that the Company maintained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule," along with all of the applicable continued listing requirements until September 22, 2026, as required by the Panel decision dated May 29, 2026, as amended.

(Press release, HCW Biologics, NOV 16, 2026, View Source [SID1234674793])

Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer

On November 16, 2026 Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, reported that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd (Roche) to evaluate PIKTOR in combination with the investigational medicine giredestrant in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Faeth will sponsor and conduct the Phase 1b/2 study (Study FTH-PIK-101), and Roche will supply giredestrant for use in the study. Activation of the PI3K/AKT/mTOR pathway is a recognized mechanism of resistance to endocrine therapy in HR+/HER2- breast cancer, providing the rationale for evaluating PIKTOR in combination with endocrine-directed agents.

"Endocrine therapy remains the backbone of treatment in HR+/HER2- breast cancer, and resistance driven by the PI3K/AKT/mTOR pathway is one of the central problems in this setting," said Anand Parikh, Chief Executive Officer of Faeth Therapeutics. "We believe PIKTOR’s multi-node approach to this pathway is well suited to patients whose disease has progressed on prior endocrine therapy, and this study will allow us to evaluate that approach in combination with giredestrant and potentially CDK4/6 regimens."

About PIKTOR

PIKTOR is an investigational, proprietary, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. According to published literature, this pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in oncology. PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), for which Faeth reported preliminary topline results on November 9, 2026. PIKTOR is also being evaluated in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April 2026 and interim data is anticipated in 2027.

(Press release, Faeth Therapeutics, NOV 16, 2026, View Source [SID1234674818])